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Abstract
Introduction: Segmental duplications (low-copy repeats) are the recently duplicated genomic segments in the
human genome that display nearly identical (> 90%) sequences and account for about 5% of euchromatic regions.
In germline, duplicated segments mediate nonallelic homologous recombination and thus cause both non-disease-
causing copy-number variants and genomic disorders. To what extent duplicated segments play a role in somatic
DNA rearrangements in cancer remains elusive. Duplicated segments often cluster and form genomic blocks
enriched with both direct and inverted repeats (complex genomic regions). Such complex regions could be fragile
and play a mechanistic role in the amplification of the ERBB2 gene in breast tumors, because repeated sequences
are known to initiate gene amplification in model systems.
Methods: We conducted polymerase chain reaction (PCR)-based assays for primary breast tumors and analyzed
publically available array-comparative genomic hybridization data to map a common copy-number breakpoint in
ERBB2-amplified primary breast tumors. We further used molecular, bioinformatics, and population-genetics
approaches to define duplication contents, structural variants, and haplotypes within the common breakpoint.
Results: We found a large (> 300-kb) block of duplicated segments that was colocalized with a common-copy
number breakpoint for ERBB2 amplification. The breakpoint that potentially initiated ERBB2 amplification localized in
a region 1.5 megabases (Mb) on the telomeric side of ERBB2. The region is very complex, with extensive
duplications of KRTAP genes, structural variants, and, as a result, a paucity of single-nucleotide polymorphism (SNP)
markers. Duplicated segments are varied in size and degree of sequence homology, indicating that duplications
have occurred recurrently during genome evolution.
Conclusions: Amplification of the ERBB2 gene in breast tumors is potentially initiated by a complex region that
has unusual genomic features and thus requires rigorous, labor-intensive investigation. The haplotypes we provide
could be useful to identify the potential association between the complex region and ERBB2 amplification.
Introduction
Gene amplification is a cellular process characterized by a
selective increase of a particular genomic region without a
proportional increase of the entire genome [1-4]. The
selective increase accompanies the overexpression of a
particular gene within the genomic region that confers a
growth advantage to the cell. The growth advantage
derived from gene amplification has long been recognized
as an important problem for cancer patients. Increased
copy numbers of proto-oncogenes, such as MYC, MYCN,
and ERBB2, leads to the overexpression of oncogene pro-
ducts that drives abnormal cell proliferation [5-9]. Abnor-
mal cell proliferation results in cancer progression and
poor patient survival [10,11]. In addition, gene amplifica-
tion is an underlying mechanism for acquired therapy
resistance, as cancer cells counteract therapeutic agents by
overactivating either therapy-target genes (for example,
BCR-ABL amplification) or alternative survival pathways
* Correspondence: tanakah@ccf.org
1Department of Molecular Genetics, Cleveland Clinic Lerner Research
Institute, Cleveland, OH 44195, USA
Full list of author information is available at the end of the article
Marotta et al. Breast Cancer Research 2012, 14:R150
http://breast-cancer-research.com/content/14/6/R150
© 2012 Marotta et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
(for example, MET amplification) [12-17]. Despite these
adverse effects on survival of cancer patients, little is
known about amplification mechanisms, and in particular,
about the initiating processes of gene amplification.
During the processes of gene amplification, extra copies
of large genomic segments accumulate in a cell. The accu-
mulation could be initiated either (a) by aberrant recombi-
nation that results in the unequal distribution of
chromosomal materials between daughter cells [18-22] or
(b) by the loss of DNA-replication control that leads to
the extra round of segmental DNA replication within a
single cell cycle [23-25]. In normal cells, these processes
are tightly regulated and are less likely to initiate gene
amplification [26,27]. In contrast, cancer cells often lack
these controls and could initiate the processes. Further-
more, cellular surveillance systems (checkpoints) that
ensure genome integrity at several stages of the cell cycle
are impaired in cancer cells [28,29] and could fail to elimi-
nate cells with extra copies. Once the accumulation is
initiated, it could lead to further accumulation by the
growth advantage conferred by the amplified gene(s).
Therefore, defining initiating processes is the key for the
better understanding of the amplification mechanism.
However, defining initiation processes in tumors in vivo is
not an easy task, as current methods for evaluating gene
amplification may not be feasible for capturing the amplifi-
cation mechanism. Gene amplification has been measured
as the increase of copy-numbers of particular genomic
regions by array-comparative genomic hybridization
(array-CGH) [30,31]. Although array-CGH covers the
entire genome and identifies amplified regions that are
important for tumor phenotypes with high confidence,
such highly amplified regions may not be the initiating
regions but rather the end products of adaptive evolution
of cancer genomes. Next-generation sequencing could
provide both copy-number profiles and somatic break-
point sequences in cancer genomes [32,33]. Because of the
copy-number increases, breakpoint sequences tend to be
biased toward amplified regions and may represent late
events during amplicon formation.
The difficulty in identifying initiation processes in
tumors in vivo is typified by the ERBB2 amplification in
breast cancer [34,35]. ERBB2 (v-erb-b2 erythroblastic leu-
kemia viral oncogene homolog 2) encodes an epidermal
growth-factor receptor HER2 (human epidermal growth
factor receptor 2) and is amplified in 10% to 20% of inva-
sive breast tumors [5,11]. As increased HER2 protein sti-
mulates growth-factor signaling pathway and drives cell
proliferation, ERBB2-amplified (HER2-positive) tumors
are associated with advanced stages, recurrence, and poor
patient survival [36,37]. Although the clinically significant
phenotype has been known for more than two decades,
the amplification mechanism remains elusive. Such infor-
mation could be important for the better understanding of
the etiology of ERBB2-amplified tumors and may have
implications in future clinical practice. ERBB2-amplified
tumors have been treated with the monoclonal antibody
trastuzumab [38]. Trastuzumab binds to HER2 and down-
regulates growth signaling and thus has significantly
improved treatment outcomes for patients with HER2-
positive tumors [39-41]. An accurate diagnosis of ERBB2
amplification is critical, because trastuzumab is solely
designed (and effective) only for tumors with ERBB2
amplification. Not only the mechanism of action, but also
fatal cardiac side effects [42,43] and high costs (more than
$100,000/year per patient) [44-46] indicate the necessity of
accurate diagnosis. Currently, fluorescence in situ hybridi-
zation (FISH) and immunohistochemistry (IHC) are two
major diagnostic tests for identifying responders and non-
responders to trastuzumab [47]. However, these current
diagnostic tests have some issues, including variable results
between institutions and ambiguous diagnoses, such as
“equivocal” in IHC [48,49]. Preanalytic factors, such as the
processing of specimens, the fixation method, and the
choice of antibodies also introduce variability [50].
Amplification mechanisms could provide new informa-
tion that may be useful to clarify issues associated with
current tests. ERBB2 amplification occurs as the amplifica-
tion of a genomic region surrounding ERBB2. A particular
haplotype within the region may be more susceptible to
ERBB2 amplification than other haplotypes. In this sce-
nario, defining haplotypes by using patients’ normal DNA
could help to clarify ambiguous cases. From the tumor-
biology point of view, it is not known why a subset of
tumors develops ERBB2 amplification. For example,
according to the cell-of-origin model [51], only a subset of
breast tumors derived from luminal progenitor cells is
HER2 positive. A better understanding of the amplification
mechanism could tell us whether the lineage determina-
tion is random or has any genetic basis.
To understand the initiating mechanisms of ERBB2
amplification, we took integrated genomic, molecular, and
bioinformatic approaches. Array-CGH data indicated that
ERBB2-amplified tumors showed a unique pattern of
copy-number transitions [52] that could result from a spe-
cific amplification mechanism (breakage-fusion- bridge
(BFB) cycles). By using the BFB cycles as a guide, we iden-
tified a genomic region that could initiate ERBB2 amplifi-
cation. The region displays a large (300-kb), complex
block of duplicated segments (sequence similarity ≥ 90%)
and several deletion polymorphisms. Such repeated
sequences could be important in the initiation of ERBB2
amplification, as it has been observed in model systems
that the frequency of gene amplification is shown to be
determined by the presence of repeated sequences at the
recombination sites [53-55]. Deletion polymorphisms of
such repeated sequences may affect the initiation, and
thus the frequency of ERBB2 amplification. Our results
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indicate an important role of a complex genomic region in
the etiology of primary breast tumors.
Materials and methods
Ethics statement
This study was approved under the Cleveland Clinic
internal Institutional Review Board (IRB07-136:
EXEMPT: Chromosome Breakage and DNA Palindrome
Formation). Specimens were obtained under the auspices
of IRB 7881 (Evaluation of Genetic and Molecular Mar-
kers in Patients with Breast Cancer). All patients con-
sented to allow their cancer specimens to be used by
researchers in an anonymized fashion. The consent form
indicates that publication will take place without identi-
fiers to protect the identity of any specific individual.
Samples and DNA extraction
Breast cancer tissues were obtained from the tissue
archives in the Pathology Department, specifically from
consenting patients (IRB 7881). HER2 status of these
tumors was determined with FISH. We first examined
hematoxylin/eosin (HE)-stained sections and confirmed
that at least 80% of cellularities were derived from tumors.
Five 10-mm sections were subject to DNA extraction.
Noncancerous normal DNA (HapMap DNA samples)
was obtained from the Coriell Institute. The sample ID is
listed in Additional file 1, Table S4.
To extract DNA, tissue sections were incubated in the
lysis buffer (100 mM NaCl/10 mM Tris⋅HCl, pH 8.0/25
mM EDTA/0.5% SDS/proteinase K) for 24 hours at 37°C,
followed by phenol/chloroform extraction and ethanol
precipitation, as described previously [54].
Array-CGH data analysis
Array-CGH datasets for 200 Her2-positive breast tumors
and control normal samples (GSE21259) [52] were
obtained from Gene Expression Omnibus (GEO) reposi-
tory in the National Center for Biotechnology Information
(NCBI) website. Partek Genomics Suite (Partek) was used
to analyze the data. Raw data were normalized by using
the Robust Multi-Array Average (RMA) method. RMA
consists of three steps: a background adjustment, quantile
normalization, and final summary. Normalized data were
used to calculate the copy number of chromosome 17 in
breast tumors.
Real-time polymerase chain reaction
We used real-time PCR for measuring copy numbers in
genomic DNA. Primers were designed for repeat-masked
sequences of the human genome (hg18) by using Mac-
Vector (see Additional file 1, Table S5). We designed pri-
mers that amplify 100- to 200-bp genomic regions. Light
Cycler 480 (Roche, Indianapolis, IN, USA) was used for
real-time PCR.
For primer sets of ERBB2, 1, 2, 4, 5, 7, and H19, PCR
reactions were carried out in a three-step 40-cycle reaction
of 95°C for 30 seconds, 60°C for 3 seconds, and 72°C for
30 seconds by using iQ SYBR Green Supermix (Bio-Rad,
Hercules, CA, USA). For primer sets of 3, 6, and 8, reac-
tions were carried out in a two-step 40-cycle reaction of
95°C for 15 seconds and 60°C for 60 seconds. We used 5
ng/μl of genomic DNA for each reaction. Each sample was
run in triplicate and was normalized to the internal con-
trol of H19 on chromosome 11. The primers used for this
analysis are described in Additional file 1, Table S5.
In silico analysis of duplication contents within the
complex genomic region
A 400-kb region of chromosome 17 (36,350,000 to
36,750,000 in the human genome (hg18)) was divided
into 500-bp segments (see Additional file 1, Table S1).
Each segment was scanned for similar regions through-
out the human genome with BLAT at the UCSC Genome
Browser. To exclude the possibility of missing some of
the duplicated segments that are located at the boundary
of the 500-bp window, we rescanned the region by using
a 2,000-bp window. We used similar criteria of sequence
homology > 90%, size > 100 bp, to define (a) intraregional
duplications (duplications within the 400-kb region), (b)
intrachromosomal duplications (duplications between
the 400-kb region and somewhere in chromosome 17
other than the 4,000-kb region), and (c) interchromoso-
mal duplications (duplications between the 400-kb region
and somewhere in the human genome other than chro-
mosome 17).
For segments that showed similarity within the 400-kb
region, a line was drawn for connecting the two fragments.
Each line corresponded to a 500-bp region that includes
the segment (sequence homology > 90%, size > 100 bp)
mapping to another 500-bp region within the region.
Segments with > 90% homology and > 100 bp were
further separated into subclassifications based on the
sequence similarities and sizes. We binned the size of seg-
ments into seven groups (100 to 500 bp, 501 to 1,000 bp,
1,001 to 1,500 bp, 1,501 to 2,000 bp, 2,001 to 2,500 bp,
2,501 to 3,000 bp, and > 3,000 bp). After separating frag-
ments into different-size bins, we defined the degree of
sequence homology for each segment.
Deletion polymorphism and PCR genotyping assay
In total, 83 structural variants were found in the Database
of Genomic Variants (DGV) [56] over a 350-kb region
(36.35 to 36.7 Mb). These variants were characterized by a
number of different studies by using a variety of different
assays (microarrays and deep sequencing) and different
numbers of samples (from one individual to HapMap
population). Two studies determined genotypes of struc-
tural variants for three major HapMap populations
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[57,58]. Only one deletion polymorphism had a minor
allele frequency > 5%.
To obtain genotypes for the deletion polymorphism,
two independent primer sets were designed for amplify-
ing either the deletion allele or the nondeletion allele (see
Additional file 1, Table S5). PCR was carried out in a
final reaction volume of 50 μl with 1.0 U Taq polymerase
(GoTaq, Promega, Madison, WI, USA), 1.5 mM MgCl2,
200 μM dNTPs, 10 pmol of each primer, and 100 ng of
genomic DNA. The thermal-cycling conditions used for
amplification consisted of an initial denaturation step at
95°C for 2 minutes, followed by 30 cycles of denaturation
at 95°C for 30 seconds, annealing at 60°C for 30 seconds,
and extension at 72°C for 30 seconds.
Repeated masked sequences
To determine whether “high-copy” repetitive elements
are enriched within the complex genomic region, we
scanned a 3-Mb region of chromosome 17: 35,000,000 to
38,000,000 (hg18) by Repeat Masker. Repeat Masker
identifies interspersed repeats and low-complexity DNA
and annotates these repeats into classes: SINE, LINE,
LTR DNA elements, low complexity, small RNA, simple
repeats, and unclassified. We binned the 3-Mb sequence
into sixty 50-kb regions and made a summary of the total
bp composition of each element (see Additional file 1,
Figure S1).
Linkage disequilibrium analysis
We used the HapMap SNP genotyping data (from
Release 28 of International HapMap project) for three
population sets: CEU, YRI, and CHB plus JPT. We took
all SNP genotypes from chromosome 17: 36,350,000 to
36,800,000. To determine linkage disequilibrium between
SNPs and the deletion polymorphism, we incorporated
the genotype of deletion polymorphism (CNVR7096.1)
from the study by Conrad et al. [58]. For convenience,
we converted the genotypes of 0 (homozygous deletion),
1 (heterozygous), and 2 (homozygous nondeletion) to a
format that could be incorporated into our existing snp
data by assigning 0 to AA, 1 to AG, and 2 to GG. We
incorporated the converted Conrad genotype data into
the HapMap release 28 data and excluded (a) individuals
from Release 28 that had not been genotyped for the
CNVR7096.1 and (b) individuals for whom more than
50% of SNP genotypes were not determined. That left us
with 178 YRI, 174 CEU, and 86 CHB+JPT individuals. D’,
LOD, and r2 values were calculated by using Haploview
4.2 [59].
Triangular plots were generated by using Haploview 4.2.
Currently Haploview 4.2 does not support the most recent
release (number 28). The previous rerelease (number 27)
does have a paucity of SNPs for the 110-kb region within
the complex genomic region, and we cannot generate a
triangular blot for the entire region. Therefore, to include
the SNPs from the release 28 into Haploview, we used
SNP tools of Microsoft Excel [60] to convert the genotypes
into a .ped file and .map file that are recognized by
Haploview.
Results
A series of recombination events from a single break
could establish the gradient of copy-number increase
toward ERBB2
The ERBB2 gene is located at chromosome 17q11.2-12.
Previous studies have shown that the amplified regions
(ERBB2 amplicon) reside within chromosomes as homo-
geneously staining regions (HSRs) [61-65], but not in
extrachromosomal, double-minute chromosomes (DMs).
Deletions of the telomeric side of ERBB2 are common
[66,67], indicating the involvement of DNA breaks in the
ERBB2 amplification. A large genomic region surround-
ing the ERBB2 gene is amplified, and within the amplified
region, ERBB2 is located in the most highly amplified
segment [52,68,69]. Copy number decreases gradually as
it goes farther from ERBB2, and ends as copy-number
loss (a gradient of copy-number increase). Therefore, elu-
cidating underlying mechanisms (a) for the intrachromo-
somal amplification and (b) for the gradient of copy-
number increase could lead to the better understanding
of the mechanism of ERBB2 amplification.
One mechanism underlying intrachromosomal amplifi-
cation is a well-established amplification mechanism called
the breakage-fusion-bridge (BFB) cycle. The BFB cycle
consists of a series of recombination events and is initiated
by a chromosome break (Figure 1A) [18,19,22,70]. The
replication of a broken chromosome would lead to a chro-
mosome structure called sister chromatid fusion, in which
sister chromatids are fused at a broken end. The resulting
chromosome with two centromeres will have another
chromosome break when two centromeres segregate into
different daughter nuclei. Such a break could be resolved
into sister-chromatid fusion and would initiate another
round of a break and fusion. Therefore, the BFB cycles
could result in the accumulation of genomic segments
within the chromosome.
The accumulation of genomic segments by the BFB
cycles could result in the gradient of copy-number
increase (Figure 1B). An initial break could occur at the
telomeric side (a blue segment) and lead to the formation
of a dicentric chromosome. In the following cycle, a chro-
mosome break at the centromeric side (a yellow segment)
would be resolved into another dicentric chromosome.
Further duplications and breaks would create a chromo-
some that accumulates segments within the chromosome.
A chromosome having a segment harboring ERBB2 (a red
segment) at very high copy number (Figure 1A, marked by
a star) could be favored because of the growth advantage
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from ERBB2 overexpression. In such a chromosome,
genomic segments flanking the ERBB2-harboring segment
would also accumulate; however, because the flanking seg-
ments do not confer a growth advantage, their copy num-
ber would not be as high as that of the ERBB2-harboring
segment. As a result, copy-number analysis for such a
chromosome would show the different degree of copy-
number increases between segments, and the highest
increase would be seen for the segment harboring ERBB2
(Figure 1B). Importantly, such a scenario could predict a
copy number transition for the initiating region of the BFB
cycles. The initiating region (next to the blue segment) is
marked by the transition from the copy-number loss to
the low-level copy-number gain (red arrow) and is situated
on the telomeric side of the ERBB2 gene.
A common copy-number breakpoint of ERBB2 amplicon
Where is the copy-number transition from a loss to a
low-level gain for the ERBB2 amplicon? Although cap-
turing low-level amplification is not as easy as detecting
highly amplified regions with array-CGH, several studies
have described such regions as the boundaries of the
ERBB2 amplicon. For example, Sircoulomb et al. [71]
analyzed 54 ERBB2-amplified breast tumors by using
high-density array-CGH microarray and showed that a
common telomeric boundary was predicted to be near
the KRT40 (keratin 40) gene. The region was also
described in another study as the boundary among
ERBB2/TOP2A co-amplified tumors [72]. To determine
whether the KRT40 region exhibits a common copy-
number breakpoint, we analyzed a publically available
array-CGH dataset that was obtained from 200 ERBB2-
amplified tumors by using tiling-path BAC arrays (Fig-
ure 2) [52]. In the dataset, most of the tumors undergo
copy-number transition from a high-level copy-number
gain (ERBB2 region, showing in red) to a loss (regions
in blue) within a 3-Mb region (chr17:35-Mb to 38-Mb
in hg18) (Figure 2, top). Some tumors clearly show the
copy-number transition from a gain to a loss near the
KRT40 gene (Figure 2, bottom).
Figure 1 The breakage-fusion-bridge (BFB) cycles in chromosome 17 create the gradient of copy-number increases for ERBB2
amplification (model). (A) A break at the telomeric side of the ERBB2 gene can initiate the BFB cycles and can result in ERBB2 amplification.
Genomic segments harboring the ERBB2 gene are shown in red; the flanking centromeric segment is shown in yellow; and a telomeric fragment
is shown in blue. In this figure, the initiating break between the blue and the white segments leads to a series of chromatid fusions and
inverted duplications (centers shown in yellow triangles) that results in a chromosome with the amplified ERBB2 gene (star). (B) The BFB cycles
can result in the gradient of copy-number increases on an array-CGH platform. Illustrated are a normal cell with two normal chromosomes and a
tumor cell with a chromosome generated by the BFB cycles (star in A) and a normal chromosome. An array-CGH experiment for measuring
relative copy number (tumor/normal) shows the gradient of copy-number increase toward the ERBB2 gene in the tumor cell (right). Red arrow,
the copy-number transition that marks the initiating region of ERBB2 amplification.
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We confirmed the copy-number transition in the sub-
set of ERBB2-amplified tumors independently by using
real-time (quantitative) PCR. We designed an eight-PCR
primer set for copy-number measurements within the
1.5-Mb region of the telomeric side of the ERBB2 gene
(Figure 3A). In particular, we measured copy numbers by
using four primer sets for the 370-kb region surrounding
KRT40. To develop a sensitive and specific assay, PCR
conditions and primers were optimized to provide copy
numbers that were nearly equal to 1 in seven normal
HapMap DNA samples (Figure 3B). Fifteen breast-tumor
tissues in which ERBB2 amplification was determined
either as ERBB2-positive or -negative with FISH were
subject to the copy-number measurements. Consistent
with the diagnoses with FISH, ERBB2 copy number
remained low in 10 ERBB2-negative (by FISH) breast
tumors (Figure 3C). In contrast, all five ERBB2-positive
tumors showed copy-number increases for the ERBB2
gene (2.3- to 14-fold). Copy number decreased dramati-
cally within the 500-kb region between ERBB2 and the
primer set 1; however, two tumors (red and blue) had a
low-level copy-number gain up to the region surrounding
KRT40. In both cases, copy number decreased to one or
less within the 370-kb region.
These results imply that a common copy-number
breakpoint for ERBB2 amplification resides in the region
near the KRT40 gene. Such a breakpoint between the
copy-number gain and loss could possibly be an initiat-
ing region for ERBB2 amplification.
A large block of duplicated segments at the common
copy-number breakpoint
What is a unique property of the genomic region sur-
rounding the KRT40 gene? Is the region fragile and prone
to DNA rearrangements? To address these questions, we
conducted an extensive characterization of the region. The
region consists of a gene family of keratin-associated pro-
tein (KRTAP) genes; 21 KRTAP genes are within the
region (Figure 4-1). The KRTAP genes encode a major
component of hair in mammals and play an essential role
Chr 17




Figure 2 A common copy-number breakpoint near the KRT40 gene. Heat maps were created from the tiling-path BAC array data by Staaf et
al. [52] and are shown for a 3-Mb region (35 to 38 Mb in hg18) of chromosome 17. The locations of ERBB2 and KRT40 are shown. Top, heat
maps of 200 ERBB2-amplified breast tumors, and bottom, heat maps of a subset (11) of tumors with copy-number breakpoints near KRT40. Red,
copy-number increase; blue, copy-number loss.
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Figure 3 Real-time polymerase chain reaction (PCR)-based copy-number measurements for the telomeric half of the ERBB2 amplicon.
Copy-number transitions for five ERBB2-amplified tumors (A), seven normal DNA samples from HapMap individuals (B), and 10 ERBB2-
nonamplified tumors (C) are shown. Each color represents a copy-number transition of an individual tumor (or HapMap DNA in B). Note that
two ERBB2-amplified tumors (blue and red in A) have a copy-number breakpoint near the KRT40 gene.
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in the formation of rigid and resistant hair shafts [73,74].
Such a large number of genes for a single gene family
could be derived from gene duplications during genome
evolution and would create complex genomic regions har-
boring segments of high sequence identities.
To determine the duplication contents, we scanned
every 500-bp window in the region by Blat (UCSC gen-
ome Browser) and plotted segments that have more
than 90% sequence homology (> 100-bp) with other
windows (Figure 4-2 and Additional file, Table S1). We
used a 100-bp cutoff rather than the conventional 1-kb
cutoff, as such a short stretch of homology could still
facilitate gene amplification [54,55]. A number of dupli-
cated segments were identified within the region, both
in the same strands (direct repeats, top) and between
the complement strands (inverted repeats, bottom). Two
large clusters of direct duplications are found (at around
the coordinate 36.5-Mb and 36.65-Mb), and one of the
duplications is 18-kb in size. These duplicated segments
are not due to the extremely high content of repetitive
elements, such as SINE elements, because the propor-
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Figure 4 A complex genomic region at a common copy-number breakpoint of the ERBB2 amplicon. For the 400-kb region (from 36.350
to 36.750 Mb in hg18), duplicated segments (1), genes (2), the locations of HapMap SNPs in four major populations (Release 27) (3), and copy-
number variants (from the Database of Genomic Variants) (4) are shown. In (1), duplicated segments are shown for either direct repeats (top) or
inverted repeats (bottom). The distribution of repetitive sequences is also shown between the direct and inverted repeats. The (2), (3), and (4)
were obtained from UCSC genome browser.
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3-Mb region surrounding the complex region (see Addi-
tional file, Figure S1).
Such extensive duplications create regions that are com-
plex and difficult to investigate with current genomic
approaches [75,76]. Failure to recognize duplications can
lead to misinterpretation of marker genotypes [77,78]. For
example, duplicated segments make it difficult to distin-
guish whether single-nucleotide changes are either the dif-
ference between duplicated segments (paralogous
sequence variants) or allelic sequence variants (single-
nucleotide polymorphisms, SNPs) [79,80]. Indeed, a set of
SNPs that tag haploblocks in the human genome (Hap-
Map SNPs, Release 27), an essential component of dis-
ease-association studies, is less well defined. An 110-kb
region on the centromeric side does not have HapMap
SNPs. Structural variants are common, and four deletion
polymorphisms are within the region listed in the Data-
base of Genomic Variants [81].
Sequence divergence between duplicated segments
Previous studies showed the association between somatic
breakpoints in cancer genomes and evolutionary break-
points [82,83]. Because segmental duplications colocalize
with evolutionary breakpoints in primate genomes
[84,85], duplication activities during primate evolution
could illustrate the unstable nature of a complex genomic
region.
First, we determined the frequency of duplicated seg-
ments for (a) duplications within the complex region, (b)
duplications between the complex region and other
regions in the same chromosome, and (c) duplications
between the complex region and other regions in differ-
ent chromosomes (Figure 5A). Duplications occurred
predominantly (73.6%) within the complex region, sug-
gesting that the recombination between duplicated seg-
ments within the region may also be frequent in somatic
cells.
The frequency of duplication events during evolution
could in part be addressed by sequence divergence
between duplications. When a segment was duplicated,
the resulting two segments were 100% identical in their
DNA sequences. Mutations could have accumulated on
each segment, which results in sequence divergence
between two segments (the proportion of sequences that
differs between duplicated segments). Assuming that
mutations accumulate in a neutral fashion, whether dupli-
cations are newer or older could be in part inferred by
using sequence divergence [86].
When we group the duplicated segments based on the
sequence identities, sequence identities vary for each
duplicated pair (Figure 5B). A large number of small dupli-
cated segments (less than 1 kb) exist in which sequence
identities differ between segments, ranging from 90% to
nearly 100%. This is also the case for larger duplicated
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Figure 5 Recurrent duplications of genomic segments within the complex region during primate evolution. (A) A pie chart showing the
proportion of duplications within the complex region, duplications between the complex region and outside of the region in the same
chromosome, and duplications between the complex region and different chromosomes (interchromosomal duplications). Intrachromosomal
duplications within the complex region account for three fourths of all the duplications. (B) Duplications within the complex region are binned
based on size (x-axis), and the number of duplications for each bin is shown in the bar graph. A unique color is given based on the sequence
identity between duplicated segments. (C) Inferred duplication activities within the complex region. Duplications are binned into four groups
based on the sequence identity between duplicated segments, and older duplications (duplications with lower sequence identities) are overlaid
by the newer duplications (duplications with higher sequence identities).
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segments; the largest segment (18 kb) has sequence iden-
tity of 95.6%, whereas most of the 1- to 2-kb segments
have 92% to 93% sequence identity.
Although gene conversion homogenizes duplicated
segments and limits our ability to date duplications pre-
cisely by using sequence divergence [87,88], these results
indicate that duplications have possibly occurred many
times within the complex region during primate genome
evolution.
Deletion polymorphisms within the complex region
Recombination between closely located repeats plays a
critical role in the initiation of gene amplification in both
mammalian cells and unicellular organisms [53-55,89].
We previously showed that as small as 79-bp DNA
inverted repeats significantly increased the occurrence of
gene amplification in mammalian cells [54]. Given the
presence of duplicated segments and their structural var-
iants within the region, a particular segment could pro-
motes ERBB2 amplification, structural variants of which
could be linked to the occurrence of ERBB2 amplifica-
tion. Identifying such a segment directly might be diffi-
cult, however, because of the complexity of the region.
As an initial step, we defined haplotypes within the
region. Different haplotypes could carry different genomic
segments, and one haplotype could be associated with
ERBB2 amplification. Because ERBB2 amplification occurs
in 10% to 20% of breast tumors in all three major popula-
tions [90,91], the haplotype should likely be a common
one in all populations. To define common haplotypes, we
first searched for common deletion polymorphisms within
the region from the Database of Genomic Variants (DGV)
and the dbSNP database. Because of the paucity and the
confounding effect from paralogous variants, SNP geno-
types may not be as reliable as those of a deletion poly-
morphism. Furthermore, we could design a PCR-based
genotyping assay for a deletion polymorphism to confirm
that the variants are allelic, but not paralogous [92].
Although a number of studies reported deletion poly-
morphisms within the region, only two studies conducted
genotyping on a population scale: copy-number variants
studies from McCarroll et al. [57] for 270 HapMap sam-
ples and Conrad et al. [58] for 450 individuals of Eur-
opean, African, and East Asian ancestry: YRI (Yoruba in
Ibadan, Nigeria), CEU (Utah residents with Northern and
Western European ancestry from the CEPH collection),
and CHB+JPT (Han Chinese in Beijing, China, and Japa-
nese in Tokyo, Japan). Among the four (in MacCarroll
et al.) and five (in Conrad et al.) deletion polymorphisms
described in these studies within the region, only one is a
common polymorphism (minor allele frequency > 5%).
The polymorphism is located at the telomeric end of the
complex region and overlaps with a 5.9-kb deletion poly-
morphism (rs72137527 from dbSNP database).
To confirm that rs72137527 is the deletion polymorph-
ism, we developed a genotyping PCR assay and geno-
typed several HapMap individuals (Figure 6). First, the
genotypes from 10 HapMap trios (father, mother, and
offspring) were consistent with the pattern of mendelian
inheritance. Thus, the deletion was confirmed as an alle-
lic polymorphism, not as paralogous variants. Second, the
genotyping results by PCR assay were highly consistent
(35 of 38 individuals) with the previous study [58], indi-
cating that rs72137527 is the deletion polymorphism
genotyped by two studies. The deletion was likely to have
occurred by nonallelic homologous recombination
(NAHR [93-96]), as it is flanked by 679-bp duplicated
segments that are 92.1% similar to each other.
Haploblocks within the complex genomic region
Deletion polymorphisms and SNPs are very often in link-
age disequilibrium (LD) [97,98]. The extent of a haplo-
type (haploblock) harboring the deletion polymorphism
can be determined by the LD analysis between the dele-
tion polymorphism and HapMap SNPs. To define the
LD, we calculated the squared correlation coefficient r2
between the deletion polymorphism and SNPs for three
major populations (Figure 7 and see Additional file,
Table S2). We found that several SNPs are in strong LD
with the deletion polymorphism in all three populations.
The LD blocks (r2 > 0.9) extend a longer distance for
CEU (27 SNPs, 114.48-kb) and CHB+JPT (31 SNPs,
137.72-kb) than YRI (17 SNPs, 65.17 kb) (see Additional
file, Table S2). We also noticed that LD decreases gradu-
ally with distance for YRI. In contrast, LD is discontinu-
ous for both CEU and CHB+JPT. The smaller LD block
for African populations is consistent with the previous
observations and may reflect a population bottleneck
when modern humans first left Africa [99].
We then used Haploview to illustrate haploblocks for
the entire region by using the SNP genotypes from the
HapMap Release 28 (Figure 7B), the newer release that
fills the 110-kb SNP gap (Figure 4) in Release 27. Consis-
tent with the LD analysis between the deletion poly-
morphism and SNPs, a large haploblock is found for the
telomeric side of the complex genomic region. However,
a haploblock is less clear and smaller for the centromeric
side of the complex region. Given the fact that the cen-
tromeric regions do not have as many duplicated seg-
ments as the telomeric region (Figure 4), having a large
gap in the HapMap Release 27 seems unexplainable. The
centromeric side may have unusual features and will
require further characterization for identifying better
genotyping markers.
Discussion
In this study, we described a common copy-number
breakpoint that potentially initiates ERBB2 amplification
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Figure 6 Genotyping polymerase chain reaction (PCR) for the deletion polymorphism rs72137527. (A) A PCR strategy for the deletion
polymorphism located at the telomeric end of the complex region. Two independent forward primers (36675156 and 36681089) were paired
with a common reverse primer (36681634) for amplifying either the nondeletion allele or the deletion allele. (B) Ethidium bromide staining gels
are shown for either the PCR amplification of the deletion allele (deletion) or that of the nondeletion allele (non-del). DNA from 8 HapMap
individuals was used.
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in primary breast tumors. The region is complex and
consists of a large number of duplicated segments that
form direct and inverted repeats. The sequence identities
between duplicates are very high (> 90%), and some of
them are more than 99% identical to each other. These
duplicated segments are associated with the KRTAP gene
family members, but not with high-copy repeats, such as
SINE elements. Duplications appear to have occurred
recurrently and predominantly within the region during
primate evolution. These results suggest that the complex
region could be more fragile than other unique loci and
could play a mechanistic role in ERBB2 amplification.
Several lines of evidence support the unstable nature of
complex genomic regions in the human genome. First,
genomic regions with duplicated segments are preferred
sites of non-disease-causing structural (copy number)
variants [56,100]. The increased frequency of structural
variants is due to the recombination between duplicated
segments (non-allelic homologous recombination, NAHR
[93-96]) in the germline. NAHR between segmental
duplications leads to deletions, duplications, and inver-
sions. Second, NAHR between duplicated segments also
causes clinical phenotypes called genomic disorders
[93-96,101]. NAHR between duplicated segments occurs
recurrently and generates either duplications or deletions
that determine the phenotypes of diseases. Recurrent
NAHR for genomic disorders further supports the
unstable nature of complex regions. Furthermore, the
blocks of duplicated segments have been shown to be the
most dynamic regions of the genome during primate evo-
lution [102-104].
These facts would strongly argue for the unstable nature
of complex genomic regions. Indeed, the important role of
segmental duplications in creating somatic mutations in
cancers is emerging. The breakpoints of isochromosome
17q, the most common isochromosome in human malig-
nancy, was located within a large (> 30) inverted segmental
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Figure 7 Haploblocks within the complex genomic region (chr17: 36,350,000-36,750,000 in hg18). (A) Linkage disequilibrium between
the deletion polymorphism (rs72137527) and HapMap single-nucleotide polymorphisms (SNPs). The r2 values between the rs72137527 and each
HapMap SNP are plotted against the physical locations of each SNP. (B) Haploblocks for the entire complex region. Triangular plots were
generated by using Haploview for the HapMap SNP genotypes from three major populations (release 28) and are shown each for a centromeric
half and a telomeric half. Red, strong linkage; white, no linkage.
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Translocation between chromosome 9 and 22, t(9;22)(q34;
q11) causes the BCR/ABL gene fusion that is the underly-
ing etiology of chronic myeloid leukemia (CML) [108].
From 10% to 20% of the translocation occurred between
the 76-kb interchromosomal segmental duplications that
are located either at the centromere proximal to ABL on
chr 9 or the centromere distal to BCR on chr 22. The
involvement of segmental duplications was also described
for the microdeletion of PTEN tumor-suppressor gene in
aggressive prostate cancers [109].
At the chromosome level, breakage-fusion-bridge (BFB)
cycles are likely an underlying mechanism of ERBB2
amplification for at least a subset of breast tumors, as (a)
the ERBB2 amplicons predominantly reside within a
chromosome [61-65], and (b) copy-number loss at the
telomeric side of the complex genomic regions (Figure 2)
indicates chromosome breaks resulting in the loss of
genetic materials. The BFB cycles have been shown to
establish intrachromosomal amplicons for other onco-
genes, such as CCND1 [110,111]. CCDN1 resides at chro-
mosome 11q13 and is frequently amplified in head and
neck tumors. CCND1 is surrounded by three clusters of
segmental duplications. These clusters have been shown
to colocalize with the boundaries of amplified regions
[112], suggesting that a series of rearrangements could
occur within these clusters during BFB cycles. In this
regard, it is noteworthy that, in addition to the complex
region described in this study, additional complex regions
exist within ERBB2 amplicons. At the centromeric side,
two large (a few hundred kb) euchromatic gaps of human
genome assembly (hg18) are noted: one at 1.5 mega-base
(Mb) and another at 3.3 Mb centromeric side of ERBB2
(see Additional file 1, Figure S2) [113]. Assembly gaps
represent regions with full duplicated DNAs and/or com-
plex, unclonable regions. Similar to CCND1 amplicon,
these duplicated DNAs within gaps may serve as sub-
strates for DNA rearrangements during BFB cycles.
We further found that other commonly amplified genes
are also in close proximity to complex genomic regions.
Among the 13 cancer genes that are most commonly
amplified and overexpressed [114], five genes (ERBB2,
CCND1, MYCL1, MDM4, and MYCN) are located within
1.5 Mb from either assembly gaps or blocks of duplicated
segments (see Additional file, Table S3). Additionally,
chromosome 1q21, a commonly amplified region in
many tumor types, has 18 gaps within 6 Mb. In contrast,
neither complex genomic regions nor assembly gaps are
seen within the 6-Mb region surrounding MYC onco-
gene, which could explain a different mechanism for
MYC amplification [115].
At the DNA level, sequence homology between dupli-
cated segments could play an initiating role in BFB cycles
and gene amplification. By using model systems, we and
others showed that inverted repeats preexisting in the
genome can nucleate the duplication of large genomic
segments [22,53-55,89]. Duplicated segments could facili-
tate the initiation of BFB cycles in two ways.
First, inverted repeats can adopt Holliday junction-like
structure by forming a cruciform. The resolution of a
cruciform results in two chromosomal parts with hair-
pin-capped ends. The replication of a centromere-har-
boring part with a hairpin-capped end results in the
formation of a dicentric chromosome and the initiation
of BFB cycles.
Second, duplicated segments could adopt a complex
secondary structure that can impose an obstacle to the
progression of replication forks (Figure 8) [116,117]. As
replication fork stalling and collapse could be processed
into one-ended DNA breaks [118], the complex regions
may have increased DNA breaks. The 5’- to 3’-end resec-
tion of one-ended DNA breaks exposes single-stranded
DNA [119]. When the end of single-stranded DNA folds
back and anneals to an inverted repeat sequence (intras-
trand annealing [55]), it would prime DNA synthesis
(break-induced replication, BIR [120]) and fill in the sin-
gle-stranded gap to create a chromosome with a hairpin-
capped end. Thus, the sequence homology between
duplicated segments could be mutagenic and initiate BFB
cycles.
In this regard, it is noteworthy that ERBB2 amplifica-
tion is absent in breast tumors from BRCA1 mutation
carriers [121]. BRCA1 binds to many proteins of DNA
damage response and repair and thus plays a critical role
in maintaining genome integrity [122]. BRCA1 is
recruited to the chromatin with damaged DNA very early
[123,124] and stimulates DNA end resection for homol-
ogy-directed repair [125,126]. As BRCA1 mutant cells
could lack efficient end resection, both mutation-free
(conservative) and mutagenic homology-directed repair
pathways could be impaired [127]. The conservative
pathway is RAD51 dependent and repairs DSBs by using
sister chromatids as a template, whereas the mutagenic
pathway can be RAD51 independent [128] and could use
repeated segments as a template. Therefore, the fact that
ERBB2 amplification is rare in tumors with BRCA1 muta-
tion may indicate that ERBB2 amplification is dependent
on mutagenic homology-directed repair. In contrast, 15%
of tumors derived from BRCA2 mutation carriers have
ERBB2 amplification [121]. BRCA2 also functions for
homology-directed repair; however, it has a more-specific
role. BRCA2 has a RAD51-binding domain and plays an
important role in conservative repair [129,130]. Indeed,
in BRCA2 mutant cells, conservative repair was impaired,
but mutagenic repair was not affected [127]. Therefore,
the distinct ERBB2 amplification tendency between
BRCA1 and BRCA2 mutant careers further suggests the
involvement of recombination between repeated seg-
ments in ERBB2 amplification.
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Alternatively, BIR initiated from one-ended DNA breaks
at the sites of collapsed replication forks could be more
processive, and repeated template switching (fork stalling
and template switching, FoSTeS [131]) could result in
complex genomic rearrangements and copy-number tran-
sition [132,133]. Newly established forks from one-ended
DNA breaks could invade into either sister chromatid or
homologues at nonallelic loci by using duplicated
sequences or microhomology [134,135]. Invading strands
can be unstable and often dissociate from template
strands. The resulting free ends would repeat invasion sev-
eral times at nonallelic loci to create complex genomic
rearrangements. Copy-number increases from such com-
plex rearrangements is relatively low, from twofold to
threefold [132]. However, duplication and triplication of
the segments could facilitate further rearrangements (for
example, unequal sister chromatid exchange) and high-
level amplification.
ERBB2 amplicons have been classified into two
groups: a large amplicon including the TOP2A gene and
a smaller, more-restricted amplicon (without TOP2A)
surrounding the ERBB2 gene [66,67]. TOP2A encodes a
DNA topoisomerase II (topoII) that controls and alters
the topologic state of DNA in several aspects of DNA


























Figure 8 Nonallelic homologous recombination (NAHR) between duplicated segments initiates the BFB cycles (model). Duplicated
segments within a complex region could adopt a complex secondary structure that can impose an obstacle for the progression of replication forks
and would generate a DSB. The 5’- to 3’-end resection of a DSB exposes single-stranded DNA that would fold back and anneal between inverted
repeat sequences (intrastrand annealing). BIR (break-induced replication) would prime DNA synthesis and fill the single-stranded gap to create a
chromosome with a hairpin-capped end. The replication of the chromosome would generate a dicentric chromosome that initiates the BFB cycles.
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metabolism, such as chromosome segregation, transcrip-
tion, and chromatin organization [136-138]. Because the
complex region is located at the telomeric side of TOP2A
gene, tumors having a breakpoint at the region belong to
the TOP2A-coamplified tumors. Whether tumors with-
out TOP2A amplification have independent common
copy-number breakpoints is an important issue for future
studies. It is also possible that an initiating break/recom-
bination occurs at the complex region (or on a further
telomeric side [139]) and, during the evolution of the
amplicon, secondary rearrangements could delete both
the region including TOP2A and the complex region
from the amplicon. TOP2A deletion in ERBB2-amplified
tumors is common [66,140]. Even in coamplified tumors,
TOP2A and ERBB2 resided in different chromosomal
domains [64,141], suggesting that secondary rearrange-
ments separated the two genes from primary amplicons.
Given the established role of repeated segments in gene
amplification in experimental systems, structural variants
of such segments could have a significant effect in the
occurrence of ERBB2 amplification [22]. Several struc-
tural variants are reported within the region, and some of
them could be good candidates for the variants. However,
defining the DNA sequences at breakpoints and identify-
ing the segments responsible for ERBB2 amplification
can be hampered by the complexity of the region. There-
fore, as an initial step, we made an effort to define the
haploblocks within the region. By combining the geno-
typing data from the deletion polymorphism and SNP
genotypes, we were able to define two blocks, one of
which showed a strong LD within the block. Our ongoing
effort for further defining haploblocks and identifying
genetic markers will provide a better understanding of
the complex region. Such genetic markers could be use-
ful, especially for the genomic regions where SNP mar-
kers are less well defined and genome-wide association
studies [142,143] may have a limited power.
Conclusions
We show here a potential initiating role of a complex
genomic region in ERBB2 amplification in breast cancer.
The genomic sequence of the region is still ambiguous,
as Genome Reference Consortium is providing an alter-
native sequence assembly for the region. Furthermore,
two large sequence gaps (in hg18) exist on the centro-
meric side of ERBB2 (see Additional file, Figure S2).
These sequence gaps likely contain many repeated
sequences and structural variants and could also be fra-
gile. Therefore, ERBB2 is flanked by many complex geno-
mic regions that may not be sufficiently investigated by
current genomic technologies. Investigating such regions
in detail, including the patterns of DNA rearrangements
at the nucleotide level, structural variants, and haplotypes
within the regions, is important for the mechanistic study
of ERBB2 amplification.
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